The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 15, 2023

Filed:

Jan. 12, 2022
Applicant:

Chugai Seiyaku Kabushiki Kaisha, Tokyo, JP;

Inventors:

Daisuke Kameoka, Tokyo, JP;

Toru Yoshizawa, Tokyo, JP;

Megumi Numata, Tokyo, JP;

Hitoshi Sasaki, Tokyo, JP;

So Yamaguchi, Tokyo, JP;

Hiroko Murata, Shizuoka, JP;

Naoka Hironiwa, Singapore, SG;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61K 9/08 (2006.01); A61K 9/19 (2006.01); C07K 14/715 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39591 (2013.01); A61K 9/08 (2013.01); A61K 9/19 (2013.01); A61K 39/3955 (2013.01); A61K 47/10 (2013.01); A61K 47/18 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); C07K 16/2866 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 14/7155 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01);
Abstract

In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof. In other non-limiting embodiments, the present disclosure relates to methods for stabilizing an antibody (for example, an anti-IL-31RA antibody) in an antibody-containing formulation, methods for suppressing antibody aggregation (aggregate formation) in an antibody-containing formulation, and methods for reducing components with charge heterogeneity in an antibody-containing formulation, the methods being characterized in that the formulation is prepared to contain arginine and/or a salt thereof, and/or sucrose and/or trehalose.


Find Patent Forward Citations

Loading…